Patents by Inventor Andrew BENDER

Andrew BENDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11937891
    Abstract: A surgical robotic system includes at least one eye tracking system positioned detect the direction of at least one user's gaze. Input derived from the eye tracking system may be used to enter commands to the surgical robotic system depending on the directions of the gaze detected or other aspects of the gaze such as pupil dilation or speed of eye movement.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: March 26, 2024
    Assignee: Asensus Surgical US, Inc.
    Inventors: Kevin Andrew Hufford, Nicholas J Bender, Alexander John Maret, Matthew Robert Penny, Paul Wilhelm Schnur, Dustin Owen Vaughan, Sevan Abashian, Michael Okyen
  • Publication number: 20230322934
    Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
    Type: Application
    Filed: October 28, 2022
    Publication date: October 12, 2023
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab-Westphal, Eileen Samy, Andrew Bender, Georgianna Varrone, Yin Wu, Daigen Xu
  • Patent number: 11485786
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: November 1, 2022
    Assignee: Merck Patent GmbH
    Inventors: Ilhan Celik, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • Publication number: 20220307066
    Abstract: The disclosure addresses methods, compositions, and kits used to detect or quantify polymerase inhibitors in biological samples. The polymerase inhibitors can be therapeutic agents, or metabolites thereof, that have been administered to a subject as part of, for example, antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) to address potential infections by, e.g., retroviruses such as HIV and other viruses reliant on reverse transcription. These methods, compositions, and kits can be applied to monitor a subject's compliance with the indicated therapies and can inform potential adjustments to the therapies.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Applicants: University of Washington, The General Hospital Corporation
    Inventors: Ayokunle Olanrewaju, Paul Drain, Jonathan Posner, Derin Sevenler, Benjamin Sullivan, Andrew Bender, Jane Zhang, Rebecca Sandlin
  • Publication number: 20200002424
    Abstract: The invention relates to the prophylaxis and/or treatment of fibrosis and/or fibrotic diseases by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from fibrosis and/or fibrotic diseases, including but not limited to systemic sclerosis (SSc). More specifically, the instant invention relates to the treatment of fibrotic diseases of the skin, lung, heart, liver and/or kidney by means of said antibody. Even more specifically, the instant invention relates to the administration of a recombinant, de-immunized monoclonal antibody targeting ?v-integrins patients suffering from systemic sclerosis, including, but not limited to systemic sclerosis of the skin, lung, heart and/or kidney by means of the anti-alpha-v integrin antibody DI17E6 and structural mutants or modifications thereof.
    Type: Application
    Filed: August 15, 2019
    Publication date: January 2, 2020
    Applicant: Merck Patent GmbH
    Inventors: Ilhan CELIK, Eike Staub, Miriam Urban, Sabine Raab, Eileen Samy, Andrew Bender, Georgianna Higginbotham, Yin Wu, Daigen Xu
  • Publication number: 20190144547
    Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 16, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Ilhan CELIK, Eike STAUB, Miriam URBAN, Sabine RAAB, Eileen SAMY, Andrew BENDER, Georgianna HIGGINBOTHAM, Yin WU, Daigen XU
  • Patent number: 10012650
    Abstract: The present invention relates to BTK occupancy assays.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: July 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: Andrew Bender, Lesley Liu-Bujalski, Albertina Pereira, Richard D. Caldwell, Roland Grenningloh, Daigen Xu
  • Publication number: 20160169894
    Abstract: The present invention relates to BTK occupancy assays.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Inventors: Andrew BENDER, Lesley LIU-BUJALSKI, Albertina PEREIRA, Richard D. CALDWELL, Roland GRENNINGLOH, Daigen XU